Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

386
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
386
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

137
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
137
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

72
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
72
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

316
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
316
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
112

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T-Cell Lymphoma With Sarcoid-Like Reaction and Secondary Myelofibrosis: A Unique Case Report and Literature Review.

Case reports in hematology·2026
Same author

Segmental Arterial Mediolysis and Other Mimics of Medium Vessel Vasculitis: A Case and Review.

Journal of clinical medicine·2026
Same author

Comment on: "Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide".

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same author

Primary hyperparathyroidism due to dual parathyroid adenomas: one orthotopic, one intrathymic in ectopic cervical thymus.

JCEM case reports·2026
Same author

<i>Streptococcus intermedius</i> Septic Arthritis of the Acromioclavicular Joint with Periarticular Abscesses in an Elderly Man with Diabetes and Recent Canine Exposure: A Case Report and Literature Review.

Infectious disease reports·2026
Same authorSame journal

Catastrophic Antiphospholipid Syndrome: A Rare but Life-Threatening Thrombotic Storm-A Case Report and Literature Review.

Case reports in rheumatology·2026

Related Experiment Video

Updated: Jun 5, 2025

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

46.8K

Enteropathic SAPHO Syndrome in Ulcerative Colitis Responsive to Bisphosphonates.

Jordan Phillipps1, Sehreen Mumtaz1, Jayesh Valecha1

  • 1Division of Rheumatology, Mayo Clinic, Jacksonville 32224, Florida, USA.

Case Reports in Rheumatology
|December 9, 2024
PubMed
Summary

SAPHO syndrome, a rare inflammatory condition, was diagnosed in a patient with ulcerative colitis (UC). Treatment with zoledronic acid led to complete symptom resolution, offering insights into managing this rare association.

Keywords:
Crohn's diseaseSAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndromebisphosphonatescase reportenteropathic SAPHO syndromeinflammatory bowel diseaseulcerative colitis

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.0K
Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
07:51

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro

Published on: March 18, 2019

5.9K

Related Experiment Videos

Last Updated: Jun 5, 2025

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

46.8K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.0K
Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
07:51

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro

Published on: March 18, 2019

5.9K

Area of Science:

  • Rheumatology
  • Gastroenterology
  • Dermatology

Background:

  • SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) syndrome is a rare inflammatory disorder affecting bone, joints, and skin.
  • While associations with inflammatory bowel disease (IBD), particularly Crohn's disease, are documented, its link with ulcerative colitis (UC) is rarely reported.
  • The clinical heterogeneity of SAPHO syndrome and overlap with IBD's extra-intestinal manifestations can lead to underdiagnosis.

Observation:

  • A case of SAPHO syndrome in a patient with UC is presented.
  • Imaging revealed sternocostal involvement, including rib enlargement and hyperostosis.
  • Bone biopsy confirmed reactive bone changes without infection or malignancy.

Findings:

  • The patient with UC and SAPHO syndrome experienced complete symptom resolution after 4 months of zoledronic acid treatment.
  • Zoledronic acid was well-tolerated, with no significant adverse events reported.
  • This case highlights a successful therapeutic approach for a rare SAPHO syndrome presentation in UC.

Implications:

  • This case provides valuable data on the diagnosis and management of SAPHO syndrome in UC patients.
  • Increased awareness and diagnostic vigilance are crucial for recognizing SAPHO syndrome in IBD patients.
  • The findings suggest zoledronic acid as a potential treatment option for SAPHO syndrome associated with UC.